You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 17, 2024

~ Buy the AMYVID (florbetapir f-18) Drug Profile, 2024 PDF Report in the Report Store ~

AMYVID Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Amyvid patents expire, and what generic alternatives are available?

Amyvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There are two patents protecting this drug.

This drug has fifty patent family members in thirty-three countries.

The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this compound. Additional details are available on the florbetapir f-18 profile page.

DrugPatentWatch® Generic Entry Outlook for Amyvid

Amyvid was eligible for patent challenges on April 6, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 30, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for AMYVID
International Patents:50
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 11
Clinical Trials: 39
Patent Applications: 221
What excipients (inactive ingredients) are in AMYVID?AMYVID excipients list
DailyMed Link:AMYVID at DailyMed
Drug patent expirations by year for AMYVID
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AMYVID
Generic Entry Date for AMYVID*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AMYVID

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Puerto RicoPhase 2
Universidad Central del CaribePhase 2
InvicroPhase 1

See all AMYVID clinical trials

Pharmacology for AMYVID

US Patents and Regulatory Information for AMYVID

AMYVID is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of AMYVID is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting AMYVID

Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-001 Apr 6, 2012 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-003 Apr 6, 2012 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-002 Apr 6, 2012 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-001 Apr 6, 2012 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-004 Oct 13, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-003 Apr 6, 2012 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for AMYVID

When does loss-of-exclusivity occur for AMYVID?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 07243712
Estimated Expiration: ⤷  Try a Trial

Austria

Patent: 39060
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0710225
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 44530
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1522624
Estimated Expiration: ⤷  Try a Trial

Costa Rica

Patent: 329
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0120135
Estimated Expiration: ⤷  Try a Trial

Patent: 0170857
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 13048
Estimated Expiration: ⤷  Try a Trial

Patent: 19048
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 99109
Estimated Expiration: ⤷  Try a Trial

Patent: 63392
Estimated Expiration: ⤷  Try a Trial

Ecuador

Patent: 088783
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 7898
Estimated Expiration: ⤷  Try a Trial

Patent: 0870389
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 99109
Estimated Expiration: ⤷  Try a Trial

Patent: 63391
Estimated Expiration: ⤷  Try a Trial

Patent: 63392
Estimated Expiration: ⤷  Try a Trial

France

Patent: C0034
Estimated Expiration: ⤷  Try a Trial

Guatemala

Patent: 0800201
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 32660
Estimated Expiration: ⤷  Try a Trial

Patent: 300028
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 3567
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 90954
Estimated Expiration: ⤷  Try a Trial

Patent: 09532349
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 63392
Estimated Expiration: ⤷  Try a Trial

Luxembourg

Patent: 232
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 08012527
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 0887
Estimated Expiration: ⤷  Try a Trial

Norway

Patent: 2090
Estimated Expiration: ⤷  Try a Trial

Patent: 18030
Estimated Expiration: ⤷  Try a Trial

Patent: 084590
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 99109
Estimated Expiration: ⤷  Try a Trial

Patent: 63392
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 99109
Estimated Expiration: ⤷  Try a Trial

Patent: 63392
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 222
Estimated Expiration: ⤷  Try a Trial

Patent: 171
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 3338
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 99109
Estimated Expiration: ⤷  Try a Trial

Patent: 63392
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0807955
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1376807
Estimated Expiration: ⤷  Try a Trial

Patent: 080106564
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 78785
Estimated Expiration: ⤷  Try a Trial

Patent: 28882
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 99366
Estimated Expiration: ⤷  Try a Trial

Patent: 0838852
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 802
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AMYVID around the world.

Country Patent Number Title Estimated Expiration
Croatia P20120135 ⤷  Try a Trial
Hungary E032660 ⤷  Try a Trial
Brazil PI0710225 derivados de estirilpiridina e sua utilização para ligar e visualizar placas amilóides ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2007126733 ⤷  Try a Trial
Slovenia 2363392 ⤷  Try a Trial
Norway 342090 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for AMYVID

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1999109 92232 Luxembourg ⤷  Try a Trial PRODUCT NAME: FLORBETAPIR (18 F)
1999109 2013/028 Ireland ⤷  Try a Trial PRODUCT NAME: FLORBETAPIR (18F), OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/12/805 20130114
1999109 13C0034 France ⤷  Try a Trial PRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114
1999109 1390030-3 Sweden ⤷  Try a Trial PRODUCT NAME: FLORBETAPIR (18F); REG. NO/DATE: EU/1/12/805 20130114
1999109 CA 2013 00035 Denmark ⤷  Try a Trial
1999109 PA2013016 Lithuania ⤷  Try a Trial PRODUCT NAME: FLORBETAPIRUM; REGISTRATION NO/DATE: EU/1/12/805 20130114
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.